Business
Ventripoint Makes Application to Amend Warrrants
(TheNewswire) Toronto, Ontario - The Newswire - October 09, 2020 ...
About this update from Ventripoint Diagnostics Ltd.
[{"type":"text","content":"Ventripoint Makes Application to Amend Warrrants\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n \n \n \n Toronto, Ontario\n \n \n - The Newswire\n \n \n - October 09, 2020\n \n \n -\nVentripoint Diagnostics Ltd.\n \n \n (\"\n \n \n Ventripoint\n \n \n \" or\nthe \"\n \n \n Company\n \n \n \"), (TSXV:VPT\n \n \n )\n \n \n (\n \n \n OTC:VPTDF)\n \n \n announces that it has made an application to the TSX Venture Exchange\n(the \"TSXV\") to amend the exercise price of\n \n \n common share purchase warrants originally issued on October\n2, 2019.\n \n \n \n \n An aggregate of 4,687,132 million warrants were\ninitially issued at an exercise price of $0.175 per common share in\nconnection with a private placement financing (see News Release on Oct\n2, 2019). Ventripoint intends to amend the exercise price of the\nwarrants from $0.175 to $0.115 per share. All other provisions of the\nwarrants will remain the same and all warrants will still expire on\nOctober 2, 2022.\n \n \n \n \n The warrant repricing is subject to final acceptance by\nTSXV Exchange.\n \n \n \n \n About Ventripoint Diagnostics\nLtd.\n \n \n \n \n Ventripoint\n \n \n has become an\nindustry leader in the application of AI (Artificial Intelligence) to\nechocardiography. Ventripoint's VMS products are powered by its\nproprietary KBR technology, which is the result of a decade of\ndevelopment and provides accurate volumetric cardiac measurements\nequivalent to MRI. This affordable, gold-standard alternative allows\ncardiologists greater confidence in the management of their patients.\nProviding better care to patients serves as a springboard and basic\nstandard for all of Ventripoint's products that guide our future\ndevelopments. In addition, VMS+ is versatile and can be used with all\nultrasound systems from any vendor supported by regulatory market\napprovals in the U.S., Europe and Canada.\n \n \n \n \n For\n \n \n further information, please\ncontact:\n \n \n \n \n Mr\n \n \n . Peter Weichler,\nDirector\n \n \n \n \n Email\n \n \n :[email protected]\n \n \n \n \n Or\n \n \n \n \n Mr. Clay Chase\n \n \n \n \n Email:\n \n \n \n [email protected]\n \n \n \n \n \n Phone: 858-456-7300\n \n \n \n \n Neither the TSX Venture Exchange nor its Regulation\nServices Provider (as that term is defined in the policies of the TSX\nVenture Exchange) accepts responsibility for the adequacy...